CEGEDIM 11.000 € (+2,04 %) L'OREAL 389.500 € (+1,49 %) LVMH 401.950 € (-0,88 %) 
STMICROELECTRONICS 46.600 € (+4,37 %) KERING 232.000 € (+1,47 %) 
DSM FIRMENICH AG 97.120 € (+2,95 %) SBM OFFSHORE 36.340 € (+0,33 %) ASML HOLDING 1 507.400 € (+1,76 %) ASM INTERNATIONAL 860.800 € (+4,21 %) ADYEN 903.000 € (+1,35 %) ORANGE 14.395 € (-4,13 %) ING GROEP N.V. 31.700 € (-1,48 %) AUBAY 51.900 € (-1,14 %) ESSILORLUXOTTICA 144.500 € (+2,30 %) ENGIE 23.800 € (+0,46 %) EURONEXT 158.400 € (-0,81 %) ENOGIA 6.380 € (0,00 %) PERNOD RICARD 60.640 € (+1,68 %) ETHERO 0.920 € (+8,24 %) ALTAREA 84.900 € (+0,24 %) ELIOR GROUP 1.880 € (-3,04 %) HEIJMANS KON 86.100 € (-3,26 %) KAUFMAN ET BROAD 21.500 € (+1,90 %) ALSTOM 15.270 € (+2,11 %) BUREAU VERITAS 27.800 € (+2,39 %) ALPES (COMPAGNIE) 17.700 € (-1,45 %) 
SHELL PLC 41.010 € (+0,58 %) TELEPERFORMANCE 70.100 € (+0,26 %) BASIC-FIT 31.600 € (-1,86 %) TIKEHAU CAPITAL 16.220 € (-2,99 %) EUROCOMMERCIAL 27.250 € (+1,68 %) DANONE 60.900 € (+1,06 %) CSG 15.134 € (-0,51 %) 
AEGON 7.832 € (-1,76 %) 74SOFTWARE 38.200 € (-0,78 %) Vusion 133.000 € (+13,68 %) HERMES INTL 1 355.000 € (+0,82 %) PEUGEOT INVEST 51.400 € (-1,72 %) PLANISWARE 23.550 € (-0,42 %) BE SEMICONDUCTOR 191.900 € (+1,72 %) SODEXO 57.400 € (+0,61 %) BROADPEAK 2.210 € (+0,45 %) BIOMERIEUX 73.250 € (+1,31 %) ARKEMA 57.500 € (+2,04 %) GTT 222.600 € (-0,62 %) VALNEVA 2.831 € (-0,77 %) GROUPE GUILLIN 20.300 € (-1,46 %) AXA 43.910 € (-2,07 %) EXOR NV 71.450 € (+0,35 %) NEXITY 5.240 € (+3,25 %) BENETEAU 5.260 € (+1,54 %) UNILEVER 54.840 € (+1,22 %) WORLDLINE 12.202 € (+1,68 %) VOPAK 47.000 € (-1,51 %) AMUNDI 92.750 € (-0,27 %) SAINT GOBAIN 71.220 € (+1,60 %) PHARMING GROUP 0.964 € (+3,92 %) SANOFI 74.390 € (-0,27 %) IMCD 95.180 € (+1,34 %) ID LOGISTICS GROUP 324.500 € (+1,25 %) |
16/09/2026 07:30
Inside Information / Other news releasesSensorion Announces Confidential Submission of Draft Registration Statement to the SEC for Potential U.S. Initial Public OfferingMontpellier (France) and Cambridge, MA (United States); September 16, 2026, 7:30am CET – Sensorion (FR001401A9Z0 – ALSEN) (“the Company”) a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the “SEC”). The confidential submission is a preliminary step in the Company's evaluation of a potential U.S. initial public offering of its ordinary shares, including in the form of American Depositary Shares (“ADSs”), and the listing of such ADSs on a U.S. national exchange, subject to market and other conditions. This press release does not, and is not intended to, constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. About SensorionSensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. ContactsInvestor Relations Press Relations Label: SENSORION NotesSource : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière